Cathal Friel reverses Open Orphan into listed Venn Life Sciences - Raglan Capital

Home
About Us
Selected Transactions
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Cathal Friel reverses Open Orphan into listed Venn Life Sciences

Home
2019
Cathal Friel reverses Open Orphan into listed Venn Life Sciences

Recent News

Interim Results for 6 months ended 30 June 2020
New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company
Open Orphan wins new contract
New £4.3m Challenge Study Contract Win
Open Orphan signs €4.4m contract with global company
Open Orphan wins €4m contract to conduct trial for new RSV treatment

Cathal Friel reverses Open Orphan into listed Venn Life Sciences

10th May 2019

https://otp.investis.com/clients/uk/amryt_pharmaceuticals_dac1/rns/regulatory-story.aspx?cid=1375&newsid=1218097

Prev
Next

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

© 2020 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences